Primary Peritoneal Carcinoma Recruiting Phase 1 / 2 Trials for Tremelimumab (DB11771)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02485990Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)Treatment